Skip to main
GKOS

Glaukos (GKOS) Stock Forecast & Price Target

Glaukos (GKOS) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 58%
Buy 33%
Hold 0%
Sell 8%
Strong Sell 0%

Bulls say

Glaukos Corp is witnessing strong growth, particularly in its Corneal Health segment, which is expected to grow by 9.4% for FY26, with significant momentum anticipated in the latter half as improved reimbursement for Epioxa is expected. The company has seen favorable sales performance for its iDose product, with revenue estimates for FY26 being adjusted upward to $205 million due to increased expectations surrounding repeat administration of the therapy, alongside an impressive gross margin of 85.1% that exceeded consensus forecasts. Additionally, Corneal Health revenue reached $24 million, surpassing consensus estimates of $18 million and demonstrating a year-over-year growth rate of 12%, indicating strong commercial traction and demand for Glaukos's innovative products.

Bears say

Glaukos Corp's recent financial performance, while showing some positive revenue growth in both domestic and international markets for glaucoma treatments, reveals a concerning trend with decreasing growth rates and emerging challenges in market dynamics. The company has revised its sales growth expectations downward for its minimally invasive glaucoma surgery (MIGS) products, reflecting anticipated headwinds in both domestic and international markets. Furthermore, the downward adjustment of 2026 and 2027 adjusted earnings per share (EPS) projections indicates a deteriorating financial outlook that may be exacerbated by competition, changes in reimbursement policies, and slower product adoption rates.

Glaukos (GKOS) has been analyzed by 12 analysts, with a consensus rating of Buy. 58% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Glaukos and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Glaukos (GKOS) Forecast

Analysts have given Glaukos (GKOS) a Buy based on their latest research and market trends.

According to 12 analysts, Glaukos (GKOS) has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $131.92, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $131.92, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Glaukos (GKOS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.